Human IL17A Recombinant Protein (HEK293 Expression) — Tag Free
Price range: $150.00 through $2,980.00
HEK293 × Chaperone-Assisted Technology
Produced using our proprietary Z-Active® platform — HEK293 mammalian expression with chaperone-assisted folding for proper disulfide bonding, N-linked glycosylation, and 5–10× higher bioactivity vs Leading Suppliers.
Overview
Interleukin-17A (IL-17A), also known as CTLA-8, is a 15-20 kDa glycosylated cytokine that plays an important role in anti-microbial and chronic inflammation. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold (1, 2). Mature human IL-17A shares 60% amino acid sequence identity with mouse and rat IL-17A (3, 4). IL-17A is secreted by Th17 cells, gamma /δ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells (2). It forms disulfide-linked homodimers as well as disulfide-linked heterodimers with IL-17F (5, 6). IL-17A exerts its effects through the transmembrane IL-17RA in complex with IL-17RC or IL-17RD (7, 8). Both IL-17RA and IL-17RC are required for responsiveness to heterodimeric IL-17A/F (7). IL-17A promotes protective mucosal and epidermal inflammation in response to microbial infection (9‑12). It induces chemokine production, neutrophil influx, and the production of antibacterial peptides (9‑11). IL-17A/F likewise induces neutrophil migration, but IL-17F does not (11). IL-17A additionally enhances the production of inflammatory mediators by rheumatoid synovial fibroblasts and contributes to TNF-alpha induced shock (4, 13). In contrast, it can protect against the progression of colitis by limiting chronic inflammation (12). IL-17A encourages the formation of autoreactive germinal centers and exacerbates the onset and progression of experimental models of autoimmunity (14, 15). IL-17A has been shown to exert either tumorigenic or anti-tumor effects (16, 17).
Specifications
- Species: human
- Expression System: HEK293
- Sequence: Gly24-Ala155
- Tag: Tag Free
- Molecular Weight: 15.1 KDa
- Purity: > 95% by Tris-Bis PAGE;> 95% by SEC-HPLC
- Endotoxin: < 1 EU/μg of the protein by LAL method.
- UniProt/Swiss-Prot: Q16552
- Available Sizes: 10 µg, 50 µg, 1 mg
Bioactivity
Measured by its ability to induce CXCL1/GRO alpha secretion in HT‑29 human colon adenocarcinoma cells. The ED50 for this effect is 0.12-1.2 ng/mL.
Formulation & Reconstitution
Formulation: 0.22 μm filtered solution of PBS, pH 7.4.
Reconstitution: 0.2 mg/mL in sterile PBS, pH7.4
Storage & Stability
Aliquot and store at -80°C. Avoid repeated freeze/thaw cycles.
Quality Assurance
Each lot is tested for purity (SDS-PAGE, SEC-HPLC), endotoxin levels (LAL method), and bioactivity. A Certificate of Analysis (COA) is provided with every order.
Safety Data Sheets & Documentation
Protocols & Support
Reconstitution Protocol
1. Briefly centrifuge the vial to collect lyophilized powder at the bottom.
2. Reconstitute in sterile deionized water or PBS to a concentration of 0.2–1.0 mg/mL.
3. Gently pipette up and down to dissolve. Do not vortex.
4. Aliquot and store at -20°C to -80°C. Avoid repeated freeze-thaw cycles.
Download Data Sheet
Complete product data sheet including batch-specific QC data, sequence information, and storage guidelines.
Download PDF Data Sheet
